



**Christopher  
am Ende  
Pfizer, Inc.**

**Host: Nikki Pohl**



***Design and Application of Clickable BACE and  $\gamma$ -Secretase Probes for Chemoproteomic Profiling and Mechanism of Action Studies***

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a decline in cognitive function and is ultimately fatal. The accumulation of amyloid  $\beta$  ( $A\beta$ ) plaques consisting primarily of  $A\beta_{42}$  have been implicated in the pathology of AD. The neurotoxic amyloid peptides are formed by sequential cleavage of the amyloid precursor protein (APP) by  $\beta$ -aspartyl secretase (BACE) and  $\gamma$ -secretase. Inhibition or modulation of both BACE and  $\gamma$ -secretase has emerged as promising approaches for treating AD. Initial BACE inhibitors in the clinic were plagued by ocular toxicity. Using quantitative chemoproteomics with a clickable photoaffinity probe, we reveal that inhibition of cathepsin D (CatD) is the principal off-target of BACE inhibitors and quantifying CatD target engagement in cells is predictive of ocular toxicity. Additionally,  $\gamma$ -secretase has also been beset by challenges with toxicity related to the inhibition of the Notch signaling pathway, which is critical for cell differentiation.  $\gamma$ -secretase modulators (GSMs) were developed to specifically reduce  $A\beta_{40/42}$  production without affecting the processing of other substrates.

**For further details, contact Mr. Steven Watkins at 5-9749**

**QCB**

**Seminar Series**

**Co-hosted by the Department  
of Chemistry and the Graduate  
Program in Biochemistry**

**FRIDAY**

**October 28**

**CHEMISTRY**

**C033**

**2:30 p.m.**